Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03417882
Title GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors BrightPath Biotherapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
St Joseph Hospital of Orange Orange California 92868 United States Details
University of Colorado Cancer Center Aurora Colorado 80045 United States Details
Florida Hosptial Cancer Center- AdventHealth Orlando Florida 32804 United States Details
Robert H Lurie Cancer Center at Northwestern University Chicago Illinois 60611 United States Details
University of Illinois at Chicago Chicago Illinois 60612 United States Details
Orchard Healthcare Skokie Illinois 60077 United States Details
Norton Healthcare Cancer Institute Louisville Kentucky 40202 United States Details
East Jefferson General Hospital Metairie Louisiana 70006 United States Details
Ocshner Cancer Institute New Orleans Louisiana 70121 United States Details
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756 United States Details
Virginia Cancer Institute Richmond Virginia 23230 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field